Clinical Evaluation of the Blazer Open-Irrigated Ablation Catheter for the Treatment of Paroxysmal Atrial Fibrillation

Inclusion Criteria: * History of recurrent symptomatic PAF with ≥2 episodes reported within the 365 days prior to enrollment o PAF is AF episodes that last ≥30 seconds in duration and terminate within 7 days. * At least 1 episode of PAF documented by Holter monitor, rhythm strip, trans-telephonic monitor (TTM), or 12-lead ECG in the 365 days prior to enrollment * Refractory to at least one Beta Blocker, Calcium Channel Blocker, Class I OR Class III anti-arrhythmic drug (AAD) * Age 18 or above, or of legal age to give informed consent specific to state and national law * Competent and willing to provide written informed consent to participate in the study and agree to comply with follow-up visits and evaluation Exclusion Criteria: * Have any of the following heart conditions within 90 days prior to enrollment: * New York Heart Association (NYHA) Class III or IV * Left ventricular ejection fraction (LVEF) \<35% * Left atrial (LA) diameter \>5.5 cm * Unstable angina or ongoing myocardial ischemia * Transmural myocardial infarction (MI) * Congenital structural heart disease that increases the risk of ablation or precludes catheter placement * Undergone any left atrial catheter or surgical ablation * Have had a coronary intervention, cardiac surgery, or other cardiac ablation within 90 days prior to enrollment * Had \>1 AF episode lasting greater than 7 days, with no episodes having lasted greater than 30 days, within the past year * Subjects regularly prescribed amiodarone therapy during the 120 days prior to enrollment * Contraindication to anticoagulation therapy * Creatinine \>2.5mg/dl or creatinine clearance \<30mL/min within 90 days (3 months) prior to enrollment * Prosthetic mitral or tricuspid heart valves * Confirmed cardiac thrombus within 30 days (1 month) prior to enrollment * Implanted pacemaker, ICD, or CRT leads within 180 days (6 months) prior to enrollment * History of CVA, TIA or PE within 180 days (6 months) prior to enrollment * Left atrial appendage closure device * Any other significant uncontrolled or unstable medical condition (e.g. sepsis, acute metabolic illness, end stage COPD) * Enrolled in any concurrent clinical trial without documented pre-approval from BSC * Women who are pregnant or plan to become pregnant within the course of their participation in the investigation * Life expectancy ≤ 2 years (730 days) per physician opinion